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Nucleotide excision repair (NER) is one of the main DNA repair pathways that protect cells against genomic damage.
Disruption of this pathway can contribute to the development of cancer and accelerate aging. Mutational characteristics
of NER-deficiency may reveal important diagnostic opportunities, as tumors deficient in NER are more sensitive to certain
treatments. Here, we analyzed the genome-wide somatic mutational profiles of adult stem cells (ASCs) from NER-deficient
Ercc1−/Δ mice. Our results indicate that NER-deficiency increases the base substitution load twofold in liver but not in small
intestinal ASCs, which coincides with the tissue-specific aging pathology observed in these mice. Moreover, NER-deficient
ASCs of both tissues show an increased contribution of Signature 8 mutations, which is a mutational pattern with unknown
etiology that is recurrently observed in various cancer types. The scattered genomic distribution of the base substitutions
indicates that deficiency of global-genome NER (GG-NER) underlies the observed mutational consequences. In line with
this, we observe increased Signature 8 mutations in a GG-NER-deficient human organoid culture, in which XPC was deleted
using CRISPR-Cas9 gene-editing. Furthermore, genomes of NER-deficient breast tumors show an increased contribution of
Signature 8 mutations compared with NER-proficient tumors. Elevated levels of Signature 8 mutations could therefore con-
tribute to a predictor of NER-deficiency based on a patient’s mutational profile.
[Supplemental material is available for this article.]
The genome is continuously exposed to mutagenic processes,
which can damage the DNA and can ultimately result in mutation
accumulation. To counteract these processes, cells exploitmultiple
DNA repair pathways that each repair specific lesions. Deficiency
of these pathways can contribute to cancer initiation and progres-
sion. To increase insight into the cellular processes that underlie
mutation accumulation, genome-wide mutational patterns of tu-
mors can be characterized (Alexandrov et al. 2013; Nik-Zainal
et al. 2016). To date, systematic analyses of tumor genomes have
revealed 30 signatures of base substitutions and six rearrangement
signatures ofmutational processes in cancer genomes (Alexandrov
et al. 2013; Nik-Zainal et al. 2016). Some links betweenmutational
signatures and DNA repair pathways have been discovered with
large-scale tumor genome analyses (Alexandrov et al. 2013; Kim
et al. 2016; Davies et al. 2017). Mutational signatures associated
with DNA repair deficiencies may have important diagnostic val-
ue. For example, several signatures have been associated with
BRCA1/2 inactivity and can consequently be predictive for a re-
sponse to PARP inhibition or cisplatin treatment (Waddell et al.
2015; Davies et al. 2017). However, linkingDNA repair deficiencies
to specific mutational signatures remains complicated, as tumors
are genomically highly unstable and multiple processes have con-
tributed to mutation accumulation, typically in a tissue-specific
manner (Alexandrov et al. 2013; Nik-Zainal et al. 2016).
Nucleotide excision repair (NER) is one of the main DNA re-
pair pathways (Iyama and Wilson 2013) and has been suggested
to underliemultiplemutational signatures, based on large-scale tu-
mor mutation analyses (Alexandrov et al. 2013). NER consists of
two subpathways: global-genome NER (GG-NER), which repairs
bulky helix-distorting lesions throughout the genome, and tran-
scription-coupled NER (TC-NER), which resolves RNA polymerase
blocking lesions during transcription (Hoeijmakers 2009; Iyama
and Wilson 2013; Marteijn et al. 2014). Somatic mutations in
ERCC2, a key factor of NER, were previously associated with
Signature 5 in urothelial tumors (Kim et al. 2016). However, not
all NER-deficient tumors are characterized by a high Signature 5
contribution (Kim et al. 2016), suggesting that NER-deficiency
might be associated with other mutational signatures as well.
We have previously shown that clonal organoid cultures can
be used tomeasuremutations that have accumulated during life or
during culturing in adult stem cells (ASCs) (Blokzijl et al. 2016;
Drost et al. 2017; Jager et al. 2018). Tissue-specific ASCs maintain
a stable genome both in vivo and in vitro and therefore provide a
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versatile system to studymutational processes in detail (Huch et al.
2015; Blokzijl et al. 2016). Furthermore, ASCs constitute a relevant
cell source to study mutational patterns, as these cells are believed
to be the cell-of-origin for specific types of cancer (Barker et al.
2009; Adams et al. 2015; Zhu et al. 2016).
Here, we used whole-genome sequencing analysis of Ercc1−/Δ
mouse organoids andXPC-knockout (XPCKO) humanorganoids to
systematically characterize the mutational consequences of NER-
deficiency. ERCC1 plays a crucial role in the core NER pathway in-
volving both GG-NER and TC-NER (Aboussekhra et al. 1995;
Sijbers et al. 1996a; Kirschner and Melton 2010; Iyama and
Wilson 2013). ERCC1 is mutated in ∼4.5% of all human tumors,
and single nucleotide polymorphisms in ERCC1 have been linked
to an increased risk of developing colorectal cancer (Ni et al. 2014).
Ercc1−/Δ mice are hemizygous for a single truncated Ercc1 allele,
which largely corrupts protein function (Weeda et al. 1997;
Dollé et al. 2011) and results in decreased NER-activity (Su et al.
2012). Ercc1−/Δ mice have five times shorter lives than wild-type
(WT) littermates (Dollé et al. 2011; Vermeij et al. 2016). The livers
of Ercc1−/Δ mice display various aging-like characteristics (Weeda
et al. 1997; Niedernhofer et al. 2006; Dollé et al. 2011; Gregg
et al. 2012), whereas other organs do not show an obvious patho-
logical phenotype. Thus, the consequences of loss of ERCC1 differ
considerably between tissues, yet the reason for this remains un-
clear. XPC is involved in the recognition of bulky DNA adducts
in the GG-NER pathway specifically (Iyama and Wilson 2013;
Puumalainen et al. 2016). Germline mutations in this gene cause
xeroderma pigmentosum, a disorder characterized by develop-
ment of various cancer types at an early
age (Sands et al. 1995; Melis et al. 2008;
Dupuy and Sarasin 2015).
In addition to themutational analy-
ses of mouse and human NER-deficiency
models, we substantiated our findings by
characterizing the genome-wide muta-
tional differences between NER-deficient
and NER-proficient tumors from a breast
cancer cohort (Nik-Zainal et al. 2016).
Results
Loss of NER protein ERCC1 increases the
number of base substitutions in liver but
not in small intestinal mouse ASCs
To characterize the mutational conse-
quences of NER-deficiency, we generated
clonal organoid cultures from single liver
and small intestinal ASCs of three
Ercc1−/Δ mice and three WT littermates
(Fig. 1A). Whole-genome sequencing
(WGS) analysis of DNA isolated from
the clonal organoid cultures allows for re-
liable determination of the somatic mu-
tations that were accumulated during
life in the original ASCs (Blokzijl et al.
2016; Jager et al. 2018). Subclonal muta-
tions acquired after the single-cell step
will only be present in a subpopulation
of the cells and are filtered out based on
low allele frequencies (Jager et al. 2018).
We also sequenced the genomes of poly-
clonal biopsies from the tail of each mouse, which served as con-
trol samples to exclude germline variants.
We performed RNA sequencing on one clonal organoid cul-
ture from each tissue of eachmouse. Ercc1 is significantly differen-
tially expressed between WT and Ercc1−/Δ in both liver and small
intestinal ASCs (P<0.05, negative binomial test) (Fig. 1B), confirm-
ing the anticipated effects of the Ercc1 mutations at the mRNA
level. While there is some Ercc1 expression in Ercc1−/Δ ASCs, the
C-terminal domain of ERCC1 is essential in ERCC1-XPF complex
formation, and disruption of this interaction reduces the stability
of ERCC1 protein (Sijbers et al. 1996b; de Laat 1998; Tripsianes
et al. 2005). Indeed, ERCC1 protein is not detectable by immuno-
blotting in Ercc1−/Δ organoid cultures of both tissues (Fig. 1C). No
other DNA repair genes were differentially expressed between WT
and Ercc1−/Δ ASCs (Supplemental Data S1). However, the expres-
sion of eight out of nine core NER genes, including Ercc1, is higher
in WT liver ASCs than WT small intestinal ASCs (Supplemental
Fig. S1; Supplemental Table S1).
WGS analysis on the clonally expanded organoid cultures re-
vealed 4238 somatic base substitutions in the autosomal genome
of 11 clonal ASC samples (Fig. 2A; Supplemental Table S2). With
targeted deep-sequencing, we validated ∼97.5% of these base sub-
stitutions (Supplemental Data S2). Liver ASCs ofWTmice acquired
19.5 ±4.1 (mean± standard deviation) base substitutions per week.
This rate is similar in ASCs of the small intestine, at 16.1 ±3.1 mu-
tations per week, and is in line with the observation that human
liver and intestinal ASCs have similarmutation accumulation rates
in vivo (Blokzijl et al. 2016). Loss of ERCC1 induced a twofold
A
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Figure 1. Experimental setup and tissue-specific expression of Ercc1 in mouse ASCs. (A) Schematic
overview of the experimental setup used to determine the mutational patterns in single ASCs from the
liver and small intestine of mice. Biopsies from the liver and small intestine of six 15-wk-old female
mice (three Ercc1−/Δ mice and three WT littermates) were cultured in bulk for ∼1.5 wk to enrich for
ASCs. Subsequently, clonal organoids were derived from these bulk organoid cultures and expanded
for ∼1 mo, until there were enough cells to perform both WGS and RNA sequencing. As a control
sample a biopsy of the tail of each mouse was also subjected to WGS. (B) Box plots depicting normaliz-
ed Ercc1 expression in ASC organoid cultures derived from liver and small intestine of Ercc1−/Δmice (n=3
and n=3, respectively) and WT littermates (n=3 and n=4, respectively). Asterisks represent significant
differences (P<0.05, negative binomial test). (C) Western blot analysis of ERCC1 in Ercc1−/Δ andWT small
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increase (45.5 ±3.0 base substitutions per week) in the number of
base substitutions in ASCs of the liver (Fig. 2A; Supplemental Fig.
S2A).We also observed a significant increase in the number of dou-
ble base substitutions in liver ASCs lacking ERCC1 (q<0.05, t-test,
FDR correction) (Fig. 2B; Supplemental Fig. S2B; Supplemental
Table S3). Ercc1−/Δ liver ASCs acquire 0.49±0.06 double base sub-
stitutions per week, while WT liver ASCs acquire only 0.05± 0.04
double base substitutions per week. The increased number of dou-
ble base substitutions in the liver ASCs remained significant after
normalizing for the total number of base substitutions (q<0.05,
t-test, FDR correction) (Supplemental Fig. S2C), indicating a liv-
er-specific enrichment of double base substitutions in Ercc1−/Δ
ASCs compared with WT. In contrast, we did not observe a differ-
ence in mutation load between small intestinal ASCs of Ercc1−/Δ
and WT mice (Fig. 2A; Supplemental Fig. S2A) or in the number
of double base substitutions (Fig. 2B; Supplemental Fig. S2B).
In addition to the 4238 base substitutions, we identified 2116
small insertions and deletions (indels) and 21 larger deletions
(≥100 bp) in the autosomal genome of the 11 clonal ASC samples
(Supplemental Table S2). We observed similar indel numbers in
WT and Ercc1−/Δ ASCs of both tissues (Fig. 2C; Supplemental Fig.
S2D). Of note, accurate identification of indels is more challenging
than base substitutions, and, as a result, these calls may contain
more false positives. ASCs in the small intestine and liver of the
mice acquire approximately 13.3 ±3.4 indels per week, indepen-
dent of Ercc1 mutation status. Likewise, loss of ERCC1 did not in-
fluence the number or type of structural variations (SVs) in ASCs of
the small intestine and the liver (Fig. 2D; Supplemental Fig. S2E;
Supplemental Table S2). Mouse ASCs carried 0–6 deletions (medi-
an length of 539 bp) (Supplemental Table S4). Finally, a genome-
wide copy-number profile was generated to identify chromosomal
gains and losses. These profiles indicated
that all WT and Ercc1−/Δ ASCs were kar-
yotypically stable during life (Supple-
mental Fig. S3). Nevertheless, some
subclonal aneuploidies were detected in
both a WT and Ercc1−/Δ liver organoid
sample, whichmost likely occurred in vi-
tro after the clonal step, irrespective of
Ercc1 mutation status.
Mouse ASCs lacking NER protein ERCC1
show increased Signature 8 mutations
To further dissect the mutational conse-
quences of NER-deficiency, we character-
ized the mutation spectra in the mouse
ASCs. Regardless of tissue-type, the mu-
tation spectra of all assessed ASCs are pre-
dominantly characterized by C:G>A:T
mutations and C:G>T:A mutations (Fig.
3A). However, the mutation spectra
of NER-proficient and NER-deficient
ASCs differed significantly for both tis-
sues (q<0.05, χ2 test, FDR correction).
Indeed, there are some differences,
such as an increased contribution of
T:A>A:T mutations in Ercc1−/Δ ASCs
compared with WT ASCs (Fig. 3A).
To gain insight into these differenc-
es, we generated 96-channel mutational
profiles of all ASCs (Supplemental Figs.
S4, S5) and assessed the contribution of each COSMICmutational
signature (https://cancer.sanger.ac.uk/cosmic/signatures_v2) to
the average 96-channel mutational profile per group (Sup-
plemental Fig. S6B). We could reconstruct the original profiles
well with the 30 COSMIC signatures (average cosine similarity =
0.95) (Supplemental Fig. S6A). The contribution of the COSMIC
signatures is significantly different between NER-proficient
and NER-deficient ASC groups for both liver and small intestine
(d> dWT_0.05 and d > dMUT_0.05, bootstrap resampling method)
(Methods; Supplemental Fig. S6C,D). We could reconstruct the
96-channel mutational profiles with the top 10 most contributing
COSMIC mutational signatures comparably well (average cosine
similarity = 0.95) (Fig. 3B,C; Supplemental Fig. S6A).
The 96-channel mutational profiles of NER-deficient liver
ASCs closely resemble Signature 8 (cosine similarity of 0.92) (Sup-
plemental Fig. S7), and Signature 8 can almost fully explain the in-
crease in base substitutions in NER-deficient liver ASCs (Fig. 3C).
The number of Signature 8 mutations is also increased in all small
intestinal ASCs of Ercc1−/Δ mice compared with WT small intesti-
nal ASCs (Fig. 3C). This finding shows that NER-deficiency can re-
sult in elevated numbers of Signature 8 mutations in ASCs,
regardless of tissue-type or overall increase in mutational load.
In addition, we performed an unbiased signature analysis by
extracting twomutational signatures de novo from themousemu-
tation catalogs using nonnegative matrix factorization (NMF)
(Supplemental Data S3; Supplemental Fig. S8). One of the identi-
fied signatures, Signature X, contributes approximately 100 muta-
tions to themutational profiles of liver ASCs and 200mutations to
small intestinal ASCs, in bothWT and Ercc1−/Δmice (Fig. 3D), sug-
gesting that this signature represents a mutational process that is
generally active in mouse ASCs. In line with this, Signature X is
A B
C D
Figure 2. Somatic mutation rates in the genomes of ASCs from liver and small intestine of WT and
Ercc1−/Δ mice. (A) Mean number of base substitutions, (B) double base substitutions, (C ) indels, and
(D) SVs acquired per autosomal genome per week in ASCs of WT liver (n =3), Ercc1−/Δ liver (n=3), WT
small intestine (n = 2), and Ercc1−/Δ small intestine (n=3). Error bars represent standard deviations.
Asterisks represent significant differences (q<0.05, two-sided t-test, FDR correction). (n.s.) Non-signifi-
cant (q≥0.05, two-sided t-test, FDR correction).
NER-deficiency associated with mutational signature
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highly similar to 96-channel mutational profiles of ASCs of the
small intestine of old mice (cosine similarity = 0.95) (Supplemen-
tal Fig. S8B; Behjati et al. 2014). As expected, this mouse signa-
ture is not similar to any of the known COSMIC signatures
identified in human tumor sequencing data (Supplemental Fig.
S8B). The other signature, Signature 8∗, is highly similar to COS-
MIC Signature 8 (cosine similarity = 0.91) (Fig. 3E; Supplemental
Fig. S8B) and has an increased contribution in Ercc1−/Δ liver ASCs
compared with WT (Fig. 3D; Supplemental Fig. S8C). Moreover,
the contribution of Signature 8∗ mutations is also increased in
Ercc1−/Δ small intestinal ASCs in comparison to WT small intesti-
nal ASCs (Fig. 3D; Supplemental Fig. S8C). These findings con-
firmed that NER-deficiency can result in the accumulation of
base substitutions that show a 96-channel profile similar to COS-
MIC Signature 8.
Mutations are distributed non-
randomly throughout the genome in
cancer cells and in human ASCs
(Schuster-Böckler and Lehner 2012;
Blokzijl et al. 2016).NER is oneof thepath-
ways suggested to underlie this nonran-
dom distribution of mutations (Zheng
et al. 2014; Perera et al. 2016). First, NER-
activity has been linked to a local enrich-
ment of mutations at gene promoters
(Perera et al.2016).However,wedonotob-
serve any significant differences in the
depletion of mutations in promoters, pro-
moter-flanking, or enhancer regions be-
tween NER-proficient and NER-deficient
ASCs (Supplemental Fig. S9A). Second,
activity of TC-NER typically results in a
depletion of mutations in expressed
genes, as this pathway repairs lesions on
the transcribed strand during transcrip-
tion (Pleasance et al. 2010). Mutations
are indeed depleted in genic regions of
NER-proficient WT mouse ASCs, but the
depletion is not significantly different
in NER-deficient ASCs (n.s., Poisson
test, FDR correction) (Supplemental Fig.
S9A). Moreover, the average expression
levels of genes in which the somatic mu-
tations are located do not differ between
Ercc1−/Δ and WT ASCs (n.s., t-test, FDR
correction) (Supplemental Fig. S9B), sug-
gesting that Ercc1−/Δ ASCs do not accu-
mulate more mutations in expressed
genes. Finally, there are no obvious
changes in transcriptional strand bias, al-
though the mutation numbers are too
low to be conclusive (n=104–660 base
substitutions per mouse ASC type) (Sup-
plemental Fig. S9C). NER-deficiency
thus influences both the mutation load
and types but not the genomic dis-
tribution in mouse ASCs, suggesting
that the contribution of TC-NER to the
mutational consequences is minimal in
these cells.
Human ASCs lacking GG-NER protein XPC show increased
Signature 8 mutations
To further evaluate the link betweenNER-deficiency and Signature
8 inhumanASCs,wegenerated ahumanGG-NER-deficientXPCKO
ASC using CRISPR-Cas9 gene-editing in a human small intestinal
organoid culture (Fig. 4A).After confirmingabsenceofXPCprotein
(Fig. 4B), we passaged theXPCKO clone for∼2mo to allow the accu-
mulation of sufficient mutations for downstream analyses. Similar
to the Ercc1−/Δmouse ASCs, the human ASC lacking XPC show an
increased number of base substitutions acquired per week (Fig. 4C;
Supplemental Table S5). In addition, the number of double base
substitutions acquiredperweekwas approximately 17 timeshigher
(Fig. 4D; Supplemental Tables S5, S6).We did not observe amarked





Figure 3. Mutational patterns of base substitutions acquired in the genomes of ASCs from liver and
small intestine of WT and Ercc1−/Δ mice. (A) Mean relative contribution of the indicated mutation types
to the mutation spectrum for each mouse ASC group. Error bars represent standard deviations. The total
number of mutations and total number of ASCs (n) per group is indicated. Asterisks indicate significant
differences in mutation spectra (q <0.05, χ2 test, FDR correction). (B) Relative contribution of the indicat-
ed COSMIC mutational signatures to the average 96-channel mutational profiles of each mouse ASC
group. Asterisks indicate significantly different signature contributions; P-values were obtained using a
bootstrap resampling approach (Methods; Supplemental Fig. S6E,F). (C) Absolute contribution of the
indicated COSMIC mutational signatures to the average 96-channel mutational profiles of each mouse
ASC group. (D) Absolute contribution of two mutational signatures that were identified by nonnegative
matrix factorization (NMF) analysis of the average 96-channel mutational profiles of each mouse ASC
group. (E) Relative contribution of each indicated context-dependent base substitution type tomutation-
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result of XPC deletion in human ASCs, nor a change in transcrip-
tional strand bias (Supplemental Fig. S10C,D). In total, ∼39% of
the increase in base substitutions in the XPCKO ASC can be ex-
plained by Signature 8 (Fig. 4E; Supplemental Fig. S10B).
NER-deficient human breast tumors show higher levels
of Signature 8 mutations
To identify whether NER-deficiency can be linked to an increase in
Signature 8 mutations in human cancer as well, we looked into
publicly availablewhole-genome sequencing data of 344 breast tu-
mors (Nik-Zainal et al. 2016). Approximately 70% of these tumors
have accumulated Signature 8 mutations (Nik-Zainal et al. 2016).
NER-status was predicted by assessing the presence of protein-cod-
ing mutations and the copy number status of 66 NER-genes (Pearl
et al. 2015). We identified 27 NER-deficient samples, 43 NER-pro-
ficient samples, and 274 with obscure NER-status.
NER-proficient and NER-deficient breast cancers have accu-
mulated a median of 3399 base substitutions (mean 3968, stan-
dard deviation 2708) and 4368 base substitutions (mean 6405,
standard deviation 6666) per sample, respectively (Supplemental
Fig. S11A). To characterize whether NER-status affects the accu-
mulation of Signature 8 mutations (https://cancer.sanger.ac.uk/
cosmic/signatures_v2), 96-channel mutational profiles of the
somatic mutations were generated for all 344 breast tumors and
the contribution of the top 18 contributing COSMIC mutational
signature was assessed (Fig. 5A; Methods). In line with previous
observations, NER-deficient tumors have acquired ∼208 addi-
tional Signature 8 mutations in comparison to NER-proficient tu-
mors (P=0.02, Wilcoxon rank-sum test) (Fig. 5B). Furthermore,
Signature 8 has the largest effect size of all 18 COSMICmutational
signatures (Supplemental Fig. S11B).
Discussion
We deleted specific NER components in an otherwise normal ge-
netic background, providing us with the unique opportunity to
directly characterize the mutational consequences of NER-defi-
ciency. Our results show that loss of
ERCC1 induces a significant increase in
the accumulation of base substitutions,
specifically in liver ASCs, which coin-
cides with the pathological aging pheno-
type observed in the liver of Ercc1−/Δmice
(Dollé et al. 2011; Gregg et al. 2012).
Liver ASCs might be more dependent
onDNA repair facilitated by ERCC1 com-
pared with small intestinal ASCs, e.g., as
a result of tissue-specific mutagen expo-
sure. In line with this, WT liver ASCs
show a higher basal expression of Ercc1
and other NER genes compared with
WT small intestinal ASCs. Alternatively,
liver ASCs might cope differently with
unrepaired DNA damage as a result of
loss of ERCC1, such as the utilization of
alternative DNA repair mechanisms to
bypass polymerase-blocking lesions or
differential induction of apoptosis or
senescence.
ERCC1 is involved in multiple DNA
repair pathways, including TC-NER, GG-
NER, SSA, and crosslink repair (Al-Minawi et al. 2008; Rahn et al.
2010). Previously, it has been shown that SSA- and crosslink re-
pair-deficiencies result in an increased number of indels and SVs
in mice, whereas NER-deficiency introduces base substitutions
(Dollé et al. 2006). Since we only observe an increase in base sub-
stitutions and Ercc1−/Δ and WT mice show a similar depletion of
base substitutions in genes, the observed mutational consequenc-
es of impaired ERCC1 are most likely an effect of defective GG-
NER. In line with this, we show that GG-NER-deficiency can also
induce an increase in the number of base substitutions in a human
small intestinal organoid culture deleted for GG-NER component
XPC. More specifically, the increased base substitution load can
be largely explained by an increased contribution of Signature 8
in both systems. In line with these observations, a mutational sig-
nature similar to Signature 8 has been shown to increase with age
in neurons of NER-deficient patients (Lodato et al. 2018).
Until now, the etiology of Signature 8 was unknown (https
://cancer.sanger.ac.uk/cosmic/signatures_v2). As Signature 8 mu-
tations are also detected in healthy human and mouse ASCs
(Figs. 3C, 4E), this signature most likely represents a mutagenic
process that is generally active in normal cells and not completely
error-free repaired. Signature 8 is characterized by C:G>A:T muta-
tions and is associated with double base substitutions, particularly
CC:GG > AA:TT double base substitutions (Alexandrov et al. 2013;
Nik-Zainal et al. 2016). C:G>A:T mutations have been linked to
several processes, including oxidative stress (Kamiya et al. 1995;
Degtyareva et al. 2013). NER has been suggested to play a role in
the repair of tandem DNA lesions that result from oxidative stress
(Bergeron et al. 2010; Cadet et al. 2012). If left unrepaired, these le-
sions can block regular DNA polymerases but can be bypassed by
error-prone TLS polymerases, resulting in increased incorporation
of tandem mutations (Cadet et al. 2012). Moreover, it has been
shown that oxidative stress results in increased induction of dou-
ble base substitutions in NER-deficient human fibroblasts (Lee
2002). In line with this, we observe a significant increase in the
double base substitution load in mouse liver ASCs and a similar
trend in the human ASC culture as a result of NER-deficiency, al-
though the number of double base substitutions is low (n=0–23
A B
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Figure 4. Mutational consequences of XPCKO in human intestinal organoid cultures in vitro.
(A) Targeting strategy for the generation of XPCKO organoid cultures using CRISPR-Cas9 gene-editing.
(B) Western blot analysis of XPC in human XPCWT and XPCKO organoids. (C ) Number of base substitu-
tions, (D) double base substitutions, and (E) Signature 8 mutations acquired per autosomal genome
per week in human XPCWT ASCs (n=3) and an XPCKO ASC (n =1) in vitro.
NER-deficiency associated with mutational signature
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per ASC). Thus, Signature 8 could reflect oxidative DNA damage
bypassed by TLS in the absence of NER.Of note, we did not observe
an enrichment for CC:GG > AA:TT double base substitutions such
as described for Signature 8 (Nik-Zainal et al. 2016), whichmay re-
flect different activity of DNA damage processes and/or additional
repair deficiencies in human tumors but could also be due to the
low number of double base substitutions in our data set.
We did not observe a high contribution of signatures
that have been previously observed in liver cancer in ASCs of
Ercc1−/Δ livers (https://cancer.sanger.ac.uk/cosmic/signatures_v2)
(Supplemental Fig. S6B). This finding suggests that themutational
processes that underlie these signatures are only active after onco-
genic transformation or that mutagen exposure in liver cancer
(progenitor) cells is different from in vivomouse ASCs and in vitro
humanASCs. Liver cancer-specific Signature 24, for example, is as-
sociated with aflatoxin intake (Huang et al. 2017), a substance to
which our mice and organoids were not exposed. In addition, Sig-
nature 1 and Signature 5, which have been previously associated
with age (Alexandrov et al. 2015; Blokzijl et al. 2016), did not
have an increased contribution in the ASCs of progeroid Ercc1−/Δ
mice. Finally, a high contribution of mutational Signature 5 has
been linked to the presence of somatic mutations in ERCC2, a
key factor in both TC-NER and GG-NER, in human urothelial can-
cer (Iyama andWilson 2013; Kim et al. 2016). However, we did not
observe an increase in Signature 5 contribution in the ASCs with-
out ERCC1 or XPC. This discrepancy in mutational consequences
could reflect various differences between these systems, such as
different effects of the mutations on protein function, distinct
roles of the proteins, or tumor- and/or tissue-specific activity of
mutagenic damage and/or DNA repair processes.
The challenge of coupling mutational signatures to muta-
tional processes based on genome sequencing data of tumors is
illustrated by our analyses of the breast cancer genomes. As the
number of mutations attributed to a signature typically increases
at a higher mutational load and the mutational loads differ great-
ly between tumor types (Alexandrov et al. 2013), it is important
to compare signature contributions between samples within a
single tumor type. Our analyses show that genomes of NER-defi-
cient breast cancer patients have an elevated number of Signature
8 mutations, which is in line with our observations in the ASCs.
Signature 8 is found in many tumor types, including medul-
loblastoma, bladder cancer, and bone cancer (Alexandrov et al.
2013, 2018). Furthermore, Signature 8 contributes to the muta-
tional profile of the majority of breast cancer tumors (Alexandrov
et al. 2013; Nik-Zainal et al. 2016). Our results show that, besides
the mutational status of core NER genes, elevation of the number
of Signature 8 mutations as compared to the average number of
such mutations in a tumor type might contribute to future predic-
tors of (GG-)NER-deficiency. It should be noted that the presence
of Signature 8 mutations alone is not conclusive for NER status.
Further optimization of mutational signature definitions may aid
to fully discriminate NER-deficient from NER-proficient tumors.
Furthermore, clinical studies will be required to demonstrate the
added predictive value of Signature 8 for NER-deficiency detection
and treatment response stratification.
Methods
Mouse and human tissue material
Ercc1−/Δ mice were generated and maintained as previously de-
scribed (Vermeij et al. 2016). The tissues were harvested from three
female Ercc1−/Δmice and three female WT littermates at the age of
15 wk, which is the time at which Ercc1−/Δ mice generally start to
die as a consequence of early aging pathologies (Vermeij et al.
2016). Experiments were performed in accordance with the
Principles of Laboratory Animal Care andwithin the guidelines ap-
proved by the Dutch Ethical Committee in full accordance with
European legislation.
Human endoscopic biopsieswere performed at theUniversity
Medical Center Utrecht and the Wilhelmina Children’s Hospital.
The patients’ informed consent was obtained, and this study was
approved by the ethical committee of University Medical Center
Utrecht.
Generation of clonal Ercc1−/Δ and WT mouse organoid cultures
Single liver ASCs were isolated from livers as described previously
(Kuijk et al. 2016). Liver organoid cultures were initiated by cul-
turing the liver ASCs in BME overlaid with mouse liver culture
initiation medium (Supplemental Table S7). One and a half
weeks after culture initiation, clonal organoid liver cultures
were generated and expanded according to protocol (Jager et al.
2018) in mouse liver expansion medium (Supplemental Table
S7). Crypts were isolated from small intestines as described previ-
ously (Sato et al. 2009). Small intestinal organoid cultures were
initiated by culturing the small intestinal ASCs in Matrigel over-
laid with mouse small intestine medium (Supplemental Table
S7). Clonal small intestinal organoid cultures were generated by
picking single organoids manually and clonally expanding these
A B
Figure 5. Mutation accumulation in predicted NER-deficient and NER-proficient breast cancer whole-genomes. (A) Relative contribution of each indi-
cated context-dependent base substitution type to the average 96-channel mutational profiles of NER-deficient and NER-proficient breast cancer samples.
(B) Number of Signature 8mutations in NER-deficient and NER-proficient breast cancer whole-genomes (n=27 and n =43, respectively). Asterisk indicates
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organoid cultures according to protocol in mouse small intestine
medium (Jager et al. 2018). Culture expansion failed for the small
intestine of mouse WT1.
Generation of a clonal and subclonal XPCKO organoid culture
ClonalXPCKO organoid cultures were generated froma small intes-
tinal bulk organoid culture derived previously (Blokzijl et al. 2016)
using the CRISPR-Cas9 gene-editing technique as described in
Drost et al. (2017). One clonal human XPCKO organoid culture
was obtained and cultured for 72 d in human small intestinal orga-
noid medium (Supplemental Table S7). Subsequently, we derived
subclonal cultures of single ASCs and expanded these until suffi-
cient DNA could be isolated for WGS. This approach allowed us
to catalog the mutations that specifically accumulated between
the two clonal expansion steps in the absence of XPC (Supplemen-
tal Fig. S10A; Blokzijl et al. 2016;Drost et al. 2017; Jager et al. 2018).
As a control, WGS data of three previously established XPCWT
organoid cultures of the same human donor (donor 6) (download-
ed from https://wgs11.op.umcutrecht.nl/mutational_patterns_
ASCs/) were used (Blokzijl et al. 2016).
RNA sequencing and differential expression analysis of Ercc1−/Δ
and WT mouse organoid cultures
For eachmouse (three Ercc1−/Δmice and threeWT littermates), we
performed RNA sequencing on one clonal organoid culture from
the liver and the small intestine. An additional small intestinal
organoid clone was sequenced of mice WT2 and WT3 to increase
the amount of replicates for differential expression analysis, as cul-
ture expansion failed for the small intestine ofWT1. Details on the
standard procedures of RNA isolation, library preparation, se-
quencing, and data (pre)processing can be found in the Supple-
mental Methods.
A DESeq nbinomTest was used to test for differential expres-
sion (1) of Ercc1 between Ercc1−/Δ and WT liver ASCs, (2) of Ercc1
between Ercc1−/Δ and WT small intestinal ASCs, (3) of 83 other
DNA repair genes (Casorelli et al. 2006) between Ercc1−/Δ and
WT liver ASCs and (4) between Ercc1−/Δ and WT small intestinal
ASCs, and (5) of nine NER genes between the WT liver and WT
small intestinal ASCs (Anders and Huber 2010). Differentially ex-
pressed genes with q<0.05 (Benjamini-Hochberg FDR multiple-
testing correction) were considered significant (Benjamini and
Hochberg 1995).
WGS and read alignment
Details on the standard procedures of DNA isolation, library prep-
aration, sequencing, and data (pre)processing can be found in the
Supplemental Methods. The WGS data of the tails confirmed that
the Ercc1−/Δ mice have compound heterozygous mutations in
Ercc1 and the WT littermates do not (Supplemental Fig. S12).
Variant calling and base substitution filtering
For both human andmouse samples, base substitutions and indels
were multi-sample-called with GATK HaplotypeCaller v3.4.46
(Van der Auwera et al. 2013; see Supplemental Methods for set-
tings). The callable genomewas determined for all sequenced sam-
ples as previously described (Jager et al. 2018; see Supplemental
Material for details on this procedure). Approximately 90±1% of
the autosomal genome was surveyed in every mouse clone
(Supplemental Table S2), and 73%–88% of the autosomal genome
was surveyed in each human subclone (Supplemental Table S5).
To obtain high-quality catalogs of somatic base substitu-
tions, we applied a comprehensive filtering procedure on the basis
of several quality parameters using SNVFI (https://github.com/
UMCUGenetics/SNVFI) (Supplemental Methods; Supplemental
Code). For the mouse samples, we also excluded variants with
any evidence in another organoid sample or control (tail) sample
of the same mouse to remove germline variants. Finally, we ex-
cluded positions with a variant allele frequency (VAF) < 0.3 in the
organoid sample to exclude mutations that were induced after
the clonal step and remaining noise. In total, 4130 out of 4238
remaining base substitutions of the mouse samples (97.5%) were
confirmed using an independent sequencing approach (Supple-
mental Data S2; Supplemental Methods).
To remove germline variants in the human samples, all vari-
ants with evidence in the control (blood) samplewere excluded for
both the clonal and subclonal organoid cultures. Subsequently, for
both the clonal and subclonal cultures, all variantswith aVAF< 0.3
were excluded. Finally, the resulting somatic base substitution cat-
alogs of the clonal and subclonal cultures were compared and all
events unique to the subclonal organoid were considered to be ac-
cumulated after theXPC deletion, that is, between the two sequen-
tial clonal expansion steps.
Clonality of organoid cultures
We validated whether the organoid samples were clonal based on
the VAF of somatic base substitutions, before the final filter step
(VAF<0.3). Each cell acquires its own set of somatic mutations
and the reads supporting a mutation will be diluted in the WGS
data of nonclonal samples, resulting in a low VAF. After extensive
filtering of somatic base substitutions, liver organoid samples from
WT1, WT2, and Ercc1−/Δ2 showed a shift in the VAF-peak away
from 0.5, and therefore these samples were excluded from further
analyses (Supplemental Fig. S13). An additional liver organoid cul-
ture from these mice was sequenced, and these samples were con-
firmed to be clonal (Supplemental Fig. S13).
Double base substitutions
We selected base substitutions from the filtered variant call format
(VCF) files that were called on consecutive bases in the mouse or
human reference genome. The double base substitutions were sub-
sequently manually checked in the Integrative Genomics Viewer
(IGV) (Robinson et al. 2011) to exclude double base substitutions
present in the control sample and/or withmany base substitutions
or indels in the region, as these are (likely) false-positives.
Indel filtering of Ercc1−/Δ and WT mouse organoid cultures
We only considered positions on the autosomal genome that were
callable and had a sequencing depth of ≥20X in both the organoid
sample and the control (tail) sample. We excluded positions that
overlap with a base substitution. Furthermore, we only considered
positions with a filter “PASS” from VariantFiltration, a GATK
phred-scaled quality score >250 and a sample-level genotype qual-
ity of 99 in both the organoid sample and the control (tail) sample.
We subsequently excluded indels that are located within 50 base
pairs of an indel called in another organoid sample and indels
with any evidence in another organoid sample or a control (tail)
sample. Finally, we excluded positionswith aVAF<0.3 in the orga-
noid sample.
SV calling and filtering of Ercc1−/Δ and WT mouse organoid
cultures
SVs were called with DELLY v0.7.2 with settings “type DEL DUP
INV TRA INS”, “map-qual 1”, “mad-cutoff 9”, “min-flank 13”,
and “geno-qual 5” (Rausch et al. 2012). We only considered SVs
NER-deficiency associated with mutational signature
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of at least 100 bp on the autosomal chromosomes that were called
with a filter “PASS” and a sample-specific genotype quality of at
least 90 in the organoid culture and the control sample. We subse-
quently excluded positions with any evidence in the control (tail)
sample. The filtered SVs were finally checked manually in IGV to
reduce false-positives, andwe excluded SVs present in the tail sam-
ple, with no visible change in the read-depth (for duplications and
deletions), and/or with many base substitutions in the region.
Genome-wide copy number profiles of Ercc1−/Δ and WT mouse
organoid cultures
To generate a virtual karyotype, genome-wide copy number states
were determined using Control-FREEC v7.2 with settings “ploidy
2”, “window 1000”, and “telocentromeric 50,000” (Boeva et al.
2012). Subsequently, the average copy number across bins of
500,000 bp was calculated and plotted to assess genome stability.
Base substitution types
We retrieved the base substitution types from all the filtered VCF
files, converted them to the six types of base substitutions that
are distinguished by convention, and generated a mutation spec-
trum (the C>T changes at NpCpG sites are considered separately
from C>T changes at other sites) for the four ASC groups
(Ercc1−/Δ liver, Ercc1−/Δ small intestine, WT liver, andWT small in-
testine), as well as XPCKO, XPCWT1, XPCWT2, and XPCWT3 ASCs.
χ2 tests were performed to determine whether the mutation spec-
tra differ significantly between (1) mouse WT and Ercc1−/Δ liver
ASCs, and (2) mouse WT and Ercc1−/Δ small intestinal ASCs. P-val-
ues were corrected for multiple testing using Benjamini-Hochberg
FDR correction, and differences inmutation rates between Ercc1−/Δ
andWTmouse ASCs with q<0.05 were considered significant.We
also retrieved the sequence context for all base substitutions to
generate the 96-channel mutational profiles for each assessed
ASC. In addition, we generated mutation spectra and 96-channel
mutational profiles of base substitutions with a VAF<0.3 that like-
ly represent subclonal mutations or noise (Supplemental Fig. S14).
Of note, the NER-deficiencywill likely also affect in vitromutation
accumulation during culturing in the mutant organoids.
The centroid of the 96-channel mutational profiles of muta-
tions with a VAF≥0.3 was calculated per mouse ASC group.
Pairwise cosine similarities of all 96-channel mutational profiles
and of all centroids were computed. We also calculated the cosine
similarities of the 96-channel mutational profiles and centroids
with all 30 COSMIC mutational signatures (https://cancer.sanger
.ac.uk/cosmic/signatures_v2) (Supplemental Fig. S7). These analy-
ses were performed with the R package MutationalPatterns
(Blokzijl et al. 2018).
De novo mutational signature extraction
We extracted two signatures using nonnegative matrix factoriza-
tion (NMF) from the 96-channel mutational profiles of the mouse
ASCs. Although the number of base substitutions is low for this di-
mension reduction approach, it does provide an unbiasedmethod
to characterize the mutational processes that have been active in
the ASCs. Subsequently, we computed the absolute contribution
of these de novo extracted signatures to the centroids of the
mouse ASC groups. We also calculated the cosine similarity of
these two mutational signatures to the 30 COSMIC mutation-
al signatures (https://cancer.sanger.ac.uk/cosmic/signatures_v2)
and to the 96-channel centroid of six small intestinal ASCs from
two old mice that was published previously (Behjati et al. 2014).
These analyses were performed with MutationalPatterns (Blokzijl
et al. 2018).
Quantification of the contribution of COSMIC mutational
signatures to the 96-channel mutational profiles
We estimated the contribution of the 30 COSMIC mutational sig-
natures (https://cancer.sanger.ac.uk/cosmic/signatures_v2) to the
centroids of each mouse ASC group and to the 96-channel muta-
tional profiles of the human organoids using MutationalPatterns
(Supplemental Figs. S6B, S10B; Blokzijl et al. 2018). We ranked
the COSMIC signatures based on the total contribution of these
signatures to the centroids of the mouse samples. Next, we itera-
tively reconstructed the centroids of the ASC groups, first using
the top two COSMIC signatures, and in each iteration the next
COSMIC signature was included until all 30 signatures were
used. The cosine similarity was calculated between the original
and the reconstructed centroid for each mouse ASC group
(Supplemental Fig. S6A). As expected, the addition of more signa-
tures increases the similarity of the reconstructed centroids with
the original centroids, but after 10 COSMIC signatures, the cosine
similarities plateau (Supplemental Fig. S6A). Therefore, we used
the signature contribution with this subset of 10 COSMIC signa-
tures to the centroids of the four ASC groups (Fig. 3B,C).
We have also performed the mutational signature analyses
with the 60 SBS COSMIC mutational signatures (v3, https://
cancer.sanger.ac.uk/cosmic/signatures/SBS/) (Alexandrov et al.
2018).We observe a similar increase inmutations of this latest ver-
sion of Signature 8 (Supplemental Fig. S15). However, as the man-
uscript of COSMIC signatures v3 has not been published yet, these
SBS signatures may be subject to change.
Determination of the statistical significance of differences
in signature contributions
A bootstrap resampling—similar to that performed in Zou et al.
(2018)—was applied to generate 7000 replicas of the 96-channel
mutational profile of each WT liver ASC (n=3), which yielded
21,000 WT liver replicas in total. Subsequently, three replicas
were randomly selected and the relative contribution of 30
COSMIC signatures was determined for their centroid. Euclidean
distance dWT was calculated between the relative signature contri-
butions of the replicas centroid and that of the original centroid.
This was repeated 10,000 times to construct a distribution of
dWT (Supplemental Fig. S6C). Next, the threshold distance with
P-value=0.05, dWT_0.05, was identified. The same approach was
taken to generate 7000 replicas of each Ercc1−/Δ (MUT) liver ASC
(n= 3) and construct a distribution of dMUT (Supplemental Fig.
S6C). The Euclidean distance d between the relative signature con-
tributions of the original WT and Ercc1−/Δ liver centroids was con-
sidered to be significantly different when d> dMUT and d> dWT.
Similarly, bootstrap distributions were generated for WT and
Ercc1−/Δ (MUT) small intestine (Supplemental Fig. S6D), with the
exception that, for the generation of the dMUT distribution, only
two replicas were randomly selected in each permutation, as there
are only two WT small intestinal ASC samples in the original set.
Finally, we repeated the same analyses for the relative con-
tributions of the subset of 10 COSMIC signatures for both
liver (Supplemental Fig. S6E) and small intestine (Supplemental
Fig. S6F).
Genomic distribution of base substitutions
To test whether the base substitutions appear more or less fre-
quently than expected in genes, promoters, promoter-flanking,
and enhancer regions, we loaded the UCSC Known Genes tables
as TxDb objects for mm10 and hg19 and the regulatory features
for mm10 and hg19 from Ensembl using biomaRt (Durinck et al.
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substitutions in the genomic regions per ASC group (Ercc1−/Δ liver,
Ercc1−/Δ small intestine, WT liver, WT small intestine, XPCKO, and
XPCWT) using a one-sided binomial test with MutationalPatterns
(Blokzijl et al. 2018), which corrects for the surveyed genomic areas
(Supplemental Figs. S9A, S10C). Two-sided Poisson tests were
performed to test for significant differences in the ratio of base
substitutionswithin a genomic region divided by the total number
of base substitutions between (1) mouse WT and Ercc1−/Δ liver
ASCs and (2) mouse WT and Ercc1−/Δ small intestinal ASCs
(Supplemental Fig. S9A). Differences in mutation rates with q<
0.05 (Benjamini-Hochberg FDR multiple-testing correction) were
considered significant.
To test whether base substitutions occur more frequently in
more highly expressed genes in the NER-deficient mouse ASCs,
we first selected base substitutions that occurred within genes in
the mouse ASCs. Per ASC group, we next determined the average
reads per kilobase per million (RPKM) mapped reads of these
genes. Two-sided t-tests were performed to test for significant dif-
ference in the average expression of genes that carry a somatic mu-
tation between (1) mouse WT and Ercc1−/Δ liver ASCs and
(2) mouse WT and Ercc1−/Δ small intestinal ASCs (Supplemental
Fig. S9B). Differences in gene expression distributions with q<
0.05 (Benjamini-Hochberg FDR multiple-testing correction) were
considered significant.
Transcriptional strand bias of base substitutions
For the base substitutions within genes, we determined whether
the mutations are located on the transcribed or the nontran-
scribed strand. To this end, we determined whether the mutated
“C” or “T” base is on the same strand as the gene definition,
which is untranscribed, or the opposite strand, which is tran-
scribed. We generated a 192-channel mutational profile per ASC
group with the relative contribution of each mutation type
with separate bars for the mutations on the transcribed and
untranscribed strand and calculated the significance of the strand
bias using a two-sided Poisson test with MutationalPatterns
(Supplemental Figs. S9C, S10D; Blokzijl et al. 2018). Further-
more, we performed two-sided Poisson tests to test whether there
is a significant difference in strand bias per mutation type be-
tween (1) mouse WT and Ercc1−/Δ liver ASCs and (2) mouse WT
and Ercc1−/Δ small intestinal ASCs (Supplemental Fig. S9C).
Differences in strand bias with an adjusted P-value q<0.05 (Ben-
jamini–Hochberg FDR multiple-testing correction) were consid-
ered significant.
Comparison of mutation rates
Two-tailed t-tests were performed to determine whether the muta-
tion rates (see SupplementalMethods) differ significantly between
(1) mouse WT and Ercc1−/Δ liver ASCs and (2) mouse WT and
Ercc1−/Δ small intestinal ASCs. Of note, these tests assume that
the data is normally distributed. Differences in mutation rates be-
tween Ercc1−/Δ and WT mouse ASCs with q<0.05 (Benjamini-
Hochberg FDR multiple-testing correction) were considered
significant.
Analysis of mutational patterns and signatures in breast cancer
whole-genome sequences
In the analysis, we included 344 breast cancer sampleswith public-
ly available SNV, indels, and CNV calls obtained from tumor-nor-
mal sample pairs (Nik-Zainal et al. 2016). Samples with a biallelic
inactivation (biallelic deletion, biallelic nonsense, splice site, non-
synonymous mutation, or frameshift indel, or two or more inde-
pendent mutations of these types) of at least one NER-related
gene (66 genes; GTF2H5 was excluded because of missing CNV
calls) (Pearl et al. 2015) are considered as NER-deficient. Samples
with no copy number depletions and no variants other than
intronic SNVs and indels in any of the 66 NER-related genes are
considered as NER-proficient. The remaining 274 samples
(∼80%) carried a singlemutation in a NER-gene, and since the oth-
er copy might be inactivated through, e.g., epigenetic silencing,
the NER functionality is unknown and therefore these samples
were excluded from the analysis.
The number of base substitutions was extracted from each
VCF file and a Wilcoxon rank-sum test was performed to deter-
mine whether the number of base substitutions is different be-
tween NER-proficient and NER-deficient samples. The 96-
channel mutational profile of each sample was generated as de-
scribed in the subsection “Base substitution types.” Subsequently,
the 96-channel mutational profile of each sample was reconstruct-
ed using the 30 mutational signatures from COSMIC, as described
in the subsection “Quantification of the contribution of COSMIC
mutational signatures to the 96-channel mutational profiles.” Sig-
natures with a contribution of <10% in all 344 samples were ex-
cluded (signatures 4, 7, 10, 11, 14, 15, 22–25, 27, 28), and the
96-channel mutational profiles were finally reconstructed using
the remaining 18 signatures. The cosine similarity between the ob-
served 96-channel mutational profile and the reconstructed pro-
file was >0.95 for all samples, which indicates a very good fit of
the signatures.
Based on this, the number of mutations per signature was
estimated for each sample. Then, for each signature, the number
of mutations was compared between the NER-deficient and NER-
proficient samples using the median difference (the median of
all pairwise differences between NER-deficient and NER-proficient
samples). A Wilcoxon rank-sum test was performed to determine
whether the number of Signature 8 mutations differs significantly
between NER-deficient and NER-proficient breast tumors.
Signature 20 is excluded from the analysis because none of the
NER-deficient or NER-proficient samples have a contribution of
Signature 20.
Data access
The raw sequencing data of the mouse samples generated in
this study have been submitted to the European Nucleotide
Archive (ENA; https://www.ebi.ac.uk/ena) under accession num-
ber ERP021379. The raw sequencing data of the human samples
generated in this study have been submitted to the European
Genome-phenome Archive (EPA; https://www.ebi.ac.uk/ega/
home) under accession number EGAS00001002681. The filtered
VCF files of the samples generated in this study have been submit-
ted to Zenodo under DOI 10.5281/zenodo.2628460. The VCF files
of base substitutions with a low VAF in the mouse samples have
been submitted to Zenodo under DOI 10.5281/zenodo.2632952.
All analysis scripts are available in the Supplemental Code
File and on https://github.com/UMCUGenetics/NER-deficiency
.git, https://github.com/UMCUGenetics/SNVFI or https://github
.com/johannabertl/BRCA_DNA_repair.
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